Novo Nordisk's experimental obesity drug CagriSema shows blood pressure benefits
By Jacob Gronholt-Pedersen COPENHAGEN (Reuters) -Novo Nordisk said on Thursday its experimental obesity drug CagriSema significantly reduced blood pressure in a late-stage trial, as the Danish drugmaker seeks to demonstrate health benefits beyond weight...
Reuters